Orbital Therapeutics is a private company, founded in 2017. The stock is not listed on any public market.
Orbital Therapeutics has no published valuation.
No funding round for Orbital Therapeutics has been disclosed yet.
Andreessen HorowitzOrbital Therapeutics develops RNA medicines that reprogram the immune system in vivo, combining circular and linear RNA engineering, lipid nanoparticle delivery, and AI-driven design. Based at 100 Binney Street in Cambridge, Massachusetts, the company's lead candidate, OTX-201, is an in vivo CAR-T therapy for autoimmune disease.
In October 2025 Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion, gaining its RNA platform and preclinical CAR-T program, following the company's earlier $270 million Series A financing led by ARCH Venture Partners.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Orbital Therapeutics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Orbital Therapeutics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Orbital Therapeutics included.
Orbital Therapeutics develops RNA medicines that reprogram the immune system in vivo, combining circular and linear RNA engineering, lipid nanoparticle delivery, and AI-driven design.
Orbital Therapeutics is private, so its shares are not available on public markets.
Orbital Therapeutics operates in Biotechnology.
Orbital Therapeutics was founded in 2017.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
